OMED - オンコメッド・ファ―マシュ―ティカルズ (OncoMed Pharmaceuticals Inc.)

OMEDのニュース

   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.  2019/04/23 13:28:01 Yahoo Finance
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based
   Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers  2019/04/18 15:01:36 Seeking Alpha
   Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting  2019/04/18 06:00:00 Benzinga
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED ) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019. Following this affirmative vote of OncoMed stockholders, the Merger is expected to occur and become fully effective not later than the close of business in New York, USA on 23 April 2019. In connection with the completion of the Merger, it is expected that Mereo will issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.
   OncoMed declares one-time contractual right dividend; shares up 7% premarket  2019/03/15 11:55:06 Seeking Alpha
   OncoMed reports Q4 results  2019/03/07 21:24:56 Seeking Alpha

calendar